Navigation Links
New Study Demonstrates Cost Effectiveness of NeuroStar TMS Therapy(R) in the Treatment of Depression
Date:11/6/2008

Cost Savings for the Health Care System May Be Expected With NeuroStar Relative to Standard Care in Patients With Inadequate Benefit to Prior Antidepressant Treatment

MALVERN, Pa., Nov. 6 /PRNewswire/ -- Neuronetics, Inc. announced today that a new health economic study evaluating the cost effectiveness of its NeuroStar TMS Therapy system in the treatment of depression was presented at the U.S. Psychiatric and Mental Health Congress in San Diego last week. This study is the largest and most comprehensive cost effectiveness study to date of TMS Therapy in patients with major depression who have failed to achieve benefit from prior antidepressant treatment, also called treatment-resistant depression (TRD).

Compared to antidepressant medication treatment as usual, NeuroStar TMS Therapy was demonstrated to be cost effective if reimbursed by third-party payers at rates up to $400 per treatment session, when only health gains were evaluated. When productivity gains due to clinical improvement and reduced caregiver costs were also included, the cost effectiveness was substantially greater. These results were found when comparing open-label NeuroStar TMS Therapy health outcomes in the FDA-indicated patient population to the health outcomes from the antidepressant medications used in the open-label, NIMH-sponsored STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study. In these open-label conditions, which are most like real-world clinical practice, NeuroStar TMS Therapy provided a net cost savings during a year of follow up when compared to antidepressant medication treatment as usual.

"Even under the most conservative modeling assumptions that we tested, TMS Therapy demonstrated an incremental cost effectiveness ratio that did not exceed the most stringent willingness to pay benchmark in the U.S. for a new treatment," said Kit N. Simpson, Dr.PH, health economist at the Medical University of South Carolina and an author of the stud
'/>"/>

SOURCE Neuronetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , ... September 04, 2015 , ... ... CEREC technology is now available at CitiDent. CEREC is a newer method for ... to saving time for patients by eliminating the need for multiple appointments, CEREC ...
(Date:9/4/2015)... Pittsburgh, PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for ... Cups could be their solution. , The patent-pending K Med Cups provide a quick and ... they help to relieve a cold, flu or cough. As a result, they enhance comfort ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference ... in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & Spa has ... are doctors and researchers at the top of their field and will be ...
(Date:9/4/2015)... ... , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and ... 400 meters final, with an impressive 44.89 seconds at the 2015 North American, Central ... in August 2015. The 44.64 time is a new NACAC Championship record. , ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what ... with the Vatican and society is. Yisrayl also provides the meaning of his own name ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , , , SILVER SPRING, ... Wellness Center has selected Artefill, the first and only FDA-approved microsphere-enhanced ... who are looking for a longer lasting dermal filler. Dr. Gonzalez ... to its proven success and effectiveness for the correction of wrinkles. ...
... , , WASHINGTON, Aug. 24 ... Veterans Affairs (VA) is taking steps to assist Veterans seeking compensation ... hidden wounds of war are being addressed vigorously and comprehensively by ... the 21st century," said Secretary Shinseki. , , ...
... , , , , ... the most powerful person in healthcare by readers of Modern ... whose name has become inextricably linked with healthcare reform, topped the ... , , "Think about healthcare reform. Now, try ...
... AUBURN HILLS, Mich., Aug. 24 ... leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable ... collaboration agreement with a major tobacco company for the ... (FSC) cigarettes. FSC cigarettes are designed to meet government ...
... , , , EMERYVILLE, Calif., ... , Inc. (NYSE-Amex: NBY ), a clinical stage ... a wide range of bacterial, viral, and fungal infections, announced today ... the 47th Annual Meeting of the Infectious Diseases Society of America ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
Cached Medicine News:Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Obama Named the Most Powerful Person in Healthcare 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 2Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... 4, 2015  Allergan plc (NYSE: AGN ) a ... , CEO and President of Allergan, will provide an overview ... Global Healthcare Conference 2015 in New York, NY ... The presentation will take place on Thursday, September ... Hyatt New York, 109 East 42nd Street, New ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... Expanding its offering of passive safety devices to protect ... Braun Medical Inc. (B. Braun) recently announced that the ... of the company,s Introcan Safety ® 3 Closed ... Safety ® IV Catheter. B. Braun made the ...
... is well known that ophthalmologists around the world often ... (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to ... efficacy. AMD Alliance International (AMDAI) is ... of a concerning surge in eye infections over the ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 3
... The Biomet Ankle ... ideally suited for,tibiotalocalcaneal ... second-generation nail affords ... fixation that incorporates ...
... clinical and economic issues of cerclage wiring, ... to maximize tension control while minimizing invasion ... efficient instrumentation with a simple technique. , ... indicated for general orthopaedic trauma surgery involving: ...
OmniAccess&trade Hip Retractor System sets a new standard in hip exposure. It provides constant, absolute exposure of the acetabulum during total hip arthroplasty and revision procedures....
... of DePuy's aggressive innovations have become the ... be equalled. The AML Total Hip ... efficiently address and effectively meet the needs ... With greater than 15 years of ...
Medicine Products: